Holger Huisman

1.4k total citations
20 papers, 1.1k citations indexed

About

Holger Huisman is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Holger Huisman has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Holger Huisman's work include Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers), Respiratory Support and Mechanisms (4 papers) and Cerebral Venous Sinus Thrombosis (4 papers). Holger Huisman is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers), Respiratory Support and Mechanisms (4 papers) and Cerebral Venous Sinus Thrombosis (4 papers). Holger Huisman collaborates with scholars based in Germany, United States and Netherlands. Holger Huisman's co-authors include Anthony Barnett, Stefano Del Prato, Hans J. Woerle, Klaus A. Dugi, Dietmar Neubacher, A. Amelsberg, Russell Jones, Sanjay Patel, Maximilian von Eynatten and Hans‐Juergen Woerle and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Stroke.

In The Last Decade

Holger Huisman

20 papers receiving 1.1k citations

Peers

Countries citing papers authored by Holger Huisman

Since Specialization

Citations

This map shows the geographic impact of Holger Huisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Huisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Huisman more than expected).

Fields of papers citing papers by Holger Huisman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Huisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Huisman. The network helps show where Holger Huisman may publish in the future.

Co-authorship network of co-authors of Holger Huisman

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Huisman. A scholar is included among the top collaborators of Holger Huisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Huisman. Holger Huisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis 2021 ·International Journal of Stroke ·José M. Ferro, Martin Bendszus, Olav Jansen, Jonathan M. Coutinho, Francesco Dentali, Adam Kobayashi, Diana Aguiar de Sousa, Lia Lucas Neto, (unknown), (unknown), Holger Huisman, Hans‐Christoph Diener, (unknown)	23
2	Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis 2020 ·Stroke ·José M. Ferro, Jonathan M. Coutinho, Olav Jansen, Martin Bendszus, Francesco Dentali, Adam Kobayashi, (unknown), (unknown), (unknown), Holger Huisman, Hans‐Christoph Diener, (unknown)	19
3	Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis 2019 ·JAMA Neurology ·José M. Ferro, Jonathan M. Coutinho, Francesco Dentali, Adam Kobayashi, А. М. Алашеев, Patrícia Canhão, (unknown), Simon Nagel, (unknown), José Mário Roriz, (unknown), (unknown), Holger Huisman, Paul A. Reilly, Hans‐Christoph Diener, (unknown)	180
4	Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis 2018 ·International Journal of Stroke ·José M. Ferro, Francesco Dentali, Jonathan M. Coutinho, Adam Kobayashi, (unknown), (unknown), Mandy Fraessdorf, Holger Huisman, Hans‐Christoph Diener	17
5	Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies 2015 ·Pneumologie ·Rikke Buhl, Eric Derom, (unknown), F. Maltais, Emílio Pizzichini, Jim Reid, (unknown), (unknown), Ann S. Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), Eric Bateman	4
6	Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies 2015 ·Pneumologie ·Rikke Buhl, R Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jean‐Louis Hébert, Antony Veale, (unknown), Ann S. Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), (unknown)	4
7	Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies 2014 ·European Respiratory Journal ·Roland Buhl, Eric Derom, Gary T. Ferguson, François Maltais, Emílio Pizzichini, Jim Reid, Henrik Watz, (unknown), Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), Eric Bateman	2
8	P256 Safety Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat In Chronic Obstructive Pulmonary Disease In Two 1-year Studies 2014 ·Thorax ·(unknown), R Abrahams, Leif Bjermer, Eric Derom, (unknown), Jean‐Louis Hébert, Antony Veale, (unknown), A. Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), Lorcan McGarvey	6
9	P254 Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat(R) Improves Outcomes Versus Mono-components In Copd In Two 1-year Studies 2014 ·Thorax ·Rikke Buhl, Eric Derom, (unknown), Emílio Pizzichini, Jim Reid, (unknown), (unknown), A. Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), François Maltais	4
10	Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat in Patients With Chronic Obstructive Pulmonary Disease: Two 1-Year Studies 2014 ·CHEST Journal ·Roland Buhl, R Abrahams, Leif Bjermer, Eric Derom, Matjaž Fležar, Jacques Hébert, (unknown), (unknown), Kay Tetzlaff, Lawrence Korducki, Holger Huisman, (unknown), Lorcan McGarvey	4
11	Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial 2013 ·The Lancet ·Anthony Barnett, Holger Huisman, Russell Jones, Maximilian von Eynatten, Sanjay Patel, Hans‐Juergen Woerle	140
12	Efficacy and Safety of Linagliptin in Elderly Patients (≥70 Years) With Type 2 Diabetes 2012 ·Canadian Journal of Diabetes ·Anthony Barnett, Holger Huisman, Russell Jones, Maximilian von Eynatten, Sanjay Patel, Hans‐Juergen Woerle, James Gamble	5
13	Effect of linagliptin monotherapy on glycaemic control and markers of β ‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial 2010 ·Diabetes Obesity and Metabolism ·Stefano Del Prato, Anthony Barnett, Holger Huisman, Dietmar Neubacher, Hans J. Woerle, Klaus A. Dugi	259
14	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours 2007 ·British Journal of Cancer ·F. Eskens, Constantijne H. Mom, André Planting, Jourik A. Gietema, A. Amelsberg, Holger Huisman, Leni van Doorn, Henry Burger, Peter Stopfer, Jaap Verweij, Elisabeth G.E. de Vries	202
15	Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule 2006 ·Journal of Clinical Oncology ·Constantijne H. Mom, Ferry A.L.M. Eskens, Jourik A. Gietema, Kees Nooter, Maja J. De Jonge, A. Amelsberg, Holger Huisman, Peter Stopfer, Elisabeth G.E. de Vries, Jaap Verweij	9
16	Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. 2005 ·Data Archiving and Networked Services (DANS) ·Peter Stopfer, (unknown), A. Amelsberg, Holger Huisman, F. Eskens, Jourik A. Gietema, (unknown), Nicole Lewis, (unknown), John B. Marshall, Jaco J. Verweij	6
17	Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration 2002 ·European Journal of Cancer ·(unknown), G. Greim, Markus Borner, K. Weigang-Köhler, Holger Huisman, A. Amelsberg, (unknown), J. Wanders, Axel‐R. Hanauske, P. Fumoleau	57
18	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors 2002 ·Journal of Clinical Oncology ·Bart C. Kuenen, Lee S. Rosen, Egbert F. Smit, (unknown), Marcel Levi, Rita Ruijter, Holger Huisman, (unknown), Paul Noordhuis, W. J. F. van der Vijgh, Godefridus J. Peters, G. Cropp, P. Scigalla, K. Hoekman, Herbert M. Pinedo, Giuseppe Giaccone	113
19	Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury 2001 ·Journal of Neurology ·(unknown), Holger Huisman, Heleen Beckerman, F.W. Bertelsmann, Chris H. Polman, Gustaaf J. Lankhorst	41
20	No Effect of Fibrates on Synthesis of Apolipoprotein(a) in Primary Cultures of Cynomolgus Monkey and Human Hepatocytes: Apolipoprotein A-I Synthesis Increased 1998 ·Biochemical and Biophysical Research Communications ·(unknown), Allard Kaptein, Holger Huisman, (unknown), P. Hans	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact